PD-1 inhibitors-based second-line therapy for metastatic gastric cancer

BACKGROUND: Metastatic gastric cancer (MGC) patients with progression on first-line treatment still have poor outcomes on chemotherapy. The KEYNOTE-061 study demonstrated that pembrolizumab, a PD-1inhibitor, was not better than paclitaxel as second-line therapy for MGC. Herein, we explored the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gou, Miaomiao, Zhang, Yong, Wang, Zhikuan, Dai, Guanghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251434/
https://www.ncbi.nlm.nih.gov/pubmed/37304303
http://dx.doi.org/10.3389/fimmu.2023.1136437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251434/
https://www.ncbi.nlm.nih.gov/pubmed/37304303
http://dx.doi.org/10.3389/fimmu.2023.1136437

Ejemplares similares